

Form PTO-1449

U.S. Department of Commerce
Patent and Trademark Office

Atty. Docket N .

57906-A/JPW/SHS/GJC

Serial N .

09/464,902

INFORMATION DISCLOSURE CITATION

(Use several sheets if necessary)

Applicants

William C. Olson, et al.

Filing Date

December 16, 1999

Group

U.S. PATENT DOCUMENTS

Examiner Initial	Document Number	Date	Name	Class	Subclass	Filing Date if Appropriate

FOREIGN PATENT DOCUMENTS

		Document Number							Date	Country	Class	Subclass	Translation	
													Yes	No

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

ele	A	Allaway, G.P., K.L. Davis-Bruno, B.A. Beaudry, E.B. Garcia, E.L. Wong, A.M. Ryder, K.W. Hasel, M.C. Gaudin, R.A. Koup, J.S. McDougal and P.J. Maddon. 1995 Expression and characterization of CD4-IgG2, a novel heterotetramer that neutralizes primary HIV type 1 isolates. AIDS Res Hum Retroviruses 11:533-539. (Exhibit 1);
	B	Allaway, G.P., A.M. Ryder, G.A. Beaudry and P.J. Maddon 1993. Synergistic inhibition of HIV-1 envelope-mediated cell fusion by CD4-based molecules in combination with antibodies to gp120 or gp41. AIDS Res. Hum. Retroviruses 9:581-587 (Exhibit 2);
	C	Amara, A., S.L. Gall, O. Schwartz, J. Salamero, M. Montes, P. Loetscher, M. Baggiolini, J.L. Virelizier and F. Arenzana-Seisdedos. 1997. HIV coreceptor downregulation as antiviral principle: SDF-1 α -dependent internalization of the chemokine receptor CXCR4 contributes to inhibition of HIV replication. J. Exp. Med. 186:139-146 (Exhibit 3);
	D	Berger, E.A. 1997. HIV entry and tropism: the chemokine receptor connection. AIDS 11 (suppl A): S3-S16 (Exhibit 4);
	E	Bieniasz, P.D., R.A. Fridell, I. Aramori, S.S.G. Ferguson, M.C. Caron and B.R. Cullen. 1997. HIV-1 induced cell fusion is mediated by multiple regions within both the viral envelope and the CCR5 co-receptor. EMBO 16:2599-2609 (Exhibit 5);
	F	Brelot, A., N. Heveker, O. Pleskoff, N. Sol and M. Alizon. 1997. Role of the first and third extracellular domains of CXCR4 in human immunodeficiency virus coreceptor activity. J. Virol. 71:4744-4751 (Exhibit 6);
	G	Chan, D.C. and P.S. Kim. 1998. HIV entry and its inhibition. Cell 93:681-684 (Exhibit 7);
	H	Connor, R.I. K.E. Sheridan, D. Ceradini, S. Choe and N.R. Landau. 1997. Change in co-receptor use correlates with disease progression in HIV-1 infected individuals. J. Exp. Med. 185:621-628 (Exhibit 8);

EXAMINER

C. Re

DATE CONSIDERED

11/27/06

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609: Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Form PTO-1449

U.S. Department of
Commerce
Patent and Trademark OfficeAtty. Docket N .
57906-A/JPW/SHS/GJCSerial No.
09/464,902Applicants
William C. Olson, et al.Filing Date
December 16, 1999

Group

INFORMATION DISCLOSURE CITATION
(Use several sheets if necessary)**U.S. PATENT DOCUMENTS**

Document Number	Date	Name	Class	Subclass	Filing Date if Appropriate

FOREIGN PATENT DOCUMENTS

Document Number	Date	Country	Class	Subclass	Translation
					Yes No

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

I	Crump, M.P., J.H. Gong, P. Loetscher, K. Rajarathnam, A. Amara, R. Arenzana-Seisdedos, J.L. Virelizier, M. Baggiolini, B.D. Sykes and I. Clark-Lewis. 1997. Solution structure and basis for functional activity of stromal-cell derived factor-1; disassociation of CXCR4 activation from binding and inhibition of HIV-1. EMBO 16:6996-7007 (Exhibit 9);
J	Dalglish, A.G., P.C.L. Beverly, P.R. Clapham, D.H. Crawford, M.F. Greaves and R.A. Weiss 1984. The CD4 (T4) antigen is an essential component of the receptor for the AIDS retrovirus Nature 312:763-766 (Exhibit 10);
K	Donzella, G.A., D. Schols, S.W. Lin, J.A. Este, K.A. Nagashima, P.J. Maddon, G.P. Allaway, T.P. Sakamar, G. Henson, E.D. Clercq and J.P. Moore. 1998 AMD3100, a small molecule inhibitor of HIV-1 entry via the CXCR4 co-receptor. Nat. Med. 4:72-77 (Exhibit 11);
L	Doranz, B.J., K. Grovit-Ferbas, M.P. Sharron, S.H. Mao, M.B. Goetz, E.S. Daar, R.W. Doms and W.A. O'Brien. 1997. A small molecule inhibitor directed against the chemokine receptor CXCR4 prevents its use as an HIV-1 co-receptor. J. Ex. Med. 186:1395-1400 (Exhibit 12);
M	Doranz, B.J., Z.-H. Lu, J. Rucker, T.-Y. Zhang, M. Sharron, Y.-H. Cen, Z.-X. Wang, H.-H. Guo, J.-G. Du, M.A. Accavitti, R.W. Doms and S.C. Peiper. 1997. Two distinct CCR5 domains can mediate co-receptor usage by human immunodeficiency virus type 1. J. Virol. 71:6305-6314 (Exhibit 13);
N	Dragic, T., V. Litwin, G.P. Allaway, S.R. Martin, Y. Huanh, K.A. Nagashima, C. Cayanan, P.J. Maddon, R.A. Koup, J.P. Moore and W.A. Moore and W.A. Paxton. 1996. HIV-1 entry into CD4+ cells is mediated by the chemokine receptor CC-CKR-5. Nature 381:667-673 (Exhibit 14);
O	Hill, C.M., D. Kwon, M. Jones, C.B. Davis, S. Marmon, B.L. Daugherty, J.A. DeMartino, M.S. Springer, D. Unutmaz and D.R. Littman. 1998. The amino terminus of human CCR5 is required for its function as a receptor for diverse human and simian immunodeficiency virus envelope glycoproteins. Virology 248:257-371 (Exhibit 15);

EXAMINER

DATE CONSIDERED

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609: Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.



Form PTO-1449

U.S. Department of Commerce
Patent and Trademark Office

Atty. Docket No.

57906-A/JPW/SHS/GJC

Serial No.

09/464,902

INFORMATION DISCLOSURE CITATION

(Use several sheets if necessary)

Applicants

William C. Olson, et al.

Filing Date

December 16, 1999

Group

U.S. PATENT DOCUMENTS

Examiner Initial	Document Number	Date	Name	Class	Subclass	Filing Date if Appropriate

FOREIGN PATENT DOCUMENTS

		Document Number	Date	Country	Class	Subclass	Translation	
							Yes	No

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

P	Kwong, P.D., R. Wyatt, J. Robinson, R.W. Sweet, J. Sodroski and W.A. Hendrickson. 1998. Structure of an HIV gp120 envelope glycoprotein in complex with the CD4 receptor and a neutralizing human antibody. <i>Nature</i> 393:648-659 (Exhibit 16);
Q	Laal, S., S. Burda, M.K. Gorny, S. Karwowska, A. Buchbinder and S. Zolla-Pazner. 1994. Synergistic neutralization of human immunodeficiency virus type 1 by combinations of human monoclonal antibodies. <i>J. Virol.</i> 68:4001-4008 (Exhibit 17);
R	Li, A., H. Katinger, M.R. Posner, L. Cavacini, S. Zolla-Pazner, M.K. Gorny, J. Sodroski, T.C. Chou, T.W. Baba and R.M. Ruprecht. 1998. Synergistic neutralization of simian-human immunodeficiency virus SHIV-vpu+ by triple and quadruple combinations of human monoclonal antibodies and high-titer antihuman immunodeficiency virus type 1 immunoglobulins. <i>J. Virol.</i> 72:3235-3240 (Exhibit 18);
S	Mack, M., B. Luckow, P.J. Nelson, J. Cihak, G. Simmons, P.R. Clapham, N. Signorel, M. Marsh, M. Stangassinger, F. Borlat, T.N.C. Wells, D. Schlondorff and A.E.I. Proudfoot. 1998. Aminooxypentane-RANTES induces CCR5 internalization but inhibits recycling: a novel inhibitory mechanisms of HIV infectivity. <i>J. Ex. Med.</i> 187:1215-1224 (Exhibit 19);
T	McKnight, A., D. Wilkinson, G. Simmons, S. Talbot, L. Picard, M. Ahuja, M. Marsh, J.A. Hoxie and P.R. Clapham. 1997. Inhibition of human immunodeficiency virus fusion by a monoclonal antibody to a co-receptor (CXCR3) is both cell type and virus strain dependent. <i>J. Virol.</i> 71:1692-1696 (Exhibit 20);
U	Strizki, J.M., J Davis-Turner, R.G. Collman, J. Hoxie and F. Gonzalez-Scarano. 1997. A monoclonal antibody (12G5) directed against CXCR4 inhibits infection with the dual-tropic human immunodeficiency virus type 1 isolate HIV-1 89.6 but not the T-tropic isolate HIV-1 HxB J. <i>Virol.</i> 71:5678-5683 (Exhibit 21);
V	Trkola, A., T. Dragic, J. Arthos, J. Binley, W.C. Olson, G.P. Allaway, C. Cheng-Mayer, J. Robinson, P.J. Maddon and J.P. Moore. 1996. CD4-dependent, antibody sensitive interactions between HIV-1 and its co-receptor CCR-5. <i>Nature</i> 384:184-187 (Exhibit 22);

EXAMINER

Cindy L.

DATE CONSIDERED

11/27/06

*EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609: Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Form PTO-1449

U.S. Department of Commerce
Patent and Trademark Office

Atty. Docket No.

57906-A/JPW/SHS/GJC

Serial No.

09/464,902

INFORMATION DISCLOSURE CITATION
(Use several sheets if necessary)

Applicants

William C. Olson, et al.

Filing Date

December 16, 1999

Group

U.S. PATENT DOCUMENTS

Examiner Initial	Document Number	Date	Name	Class	Subclass	Filing Date if Appropriate

FOREIGN PATENT DOCUMENTS

		Document Number						Date	Country	Class	Subclass	Translation	
												Yes	No

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

W	Vijh-Warrier, S., A. Pinter, W.J. Honnen and S.A. Tilley. 1996. Synergistic neutralization of human immunodeficiency virus type 1 by a chimpanzee monoclonal antibody against the V2 domain of gp120 in combination with monoclonal antibodies against the V3 loop and the CD4-binding site. J. Virol. 70:4466-4473 (Exhibit 23);
X	Wu, L., G. LaRosa, N. Kassam, C.J. Gordon, H. Heath, N. Ruffing, H. Chen, J. Humblis, M. Samson, M. Parmentier, J.P. Moore and C.R. Mackay. 1997. Interaction of chemokine receptor CCR5 with its ligands: multiple domains for HIV-1 gp120 binding and a single domain for chemokine binding. J. Exp. Med. 186:1373-1381 (Exhibit 24);
Y	Ylisastigui, L., J.J. Vizzanova, E. Drakopoulou, P. Paindavoine, C.F. Calvo, M. Parmentier, J.C. Gluckman, C. Vita and A. Benjoud. 1998. Synthetic full length and truncated RANTES inhibit HIV-1 infection of primary macrophages. AIDS 12:977-984 (Exhibit 25).
Z	Tilley, S. A., W.J. Honnen, S. Warrier, M.E. Racho, T.C. Chou, M. Girard, E. Muchmore, M. Hilgartner, D.D. Ho, M.S.C. Fung, and A. Pinter. 1991. Potent Neutralization of HIV-1 by Human and Chimpanzee Monoclonal Antibodies Directed Against Three Distinct Epitope Clusters of gp120. Sixieme Colloque Des Cent Gardes. 211-216 (Exhibit 26)
AA	Tilley, S.A., W.J. Honnen, M.E. Racho, T.C. Chou, and A. Pinter. 1992. Synergistic Neutralization of HIV-1 by Human Monoclonal Antibodies Against the V3 Loop and the CD4-Binding Site of gp120. AIDS Research and Human Retroviruses 80:4: 461-467 (Exhibit 27)
AB	Choe, H., M. Farzan, Y. Sun, N. Sullivan, B. Rollins, P.D. Ponath, L. Wu, C.R. Mackay, G. LaRosa, W. Newman, N. Gerard, C. Gerard, and J. Sodroski. The Beta-Chemokine Receptors CCR3 and CCR5 Facilitate Infection by Primary HIV-1 Isolates. Cell 85, 1135-1148 (Exhibit 28)

EXAMINER

Emily Le

DATE CONSIDERED

11/27/04

1446

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609: Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.



USPTO-1449	U.S. Department of Commerce Patent and Trademark Office	Application Number	09/464,902
		Filing Date	December 16, 1999
		First Named Inventor	William C. Olson et al.
		Art Unit	1648
		Examiner Name	Emily Le
		Attorney Docket No.	2048/57906-A/JPW/AJD

INFORMATION DISCLOSURE STATEMENT

(Use several sheets if necessary)

U.S. PATENT DOCUMENTS

Examiner Initials*	Cite No. ¹	Document Number Number-Kind Code ² (if known)	Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document

FOREIGN PATENT DOCUMENTS

Examiner Initials*	Cite No. ¹	Foreign Patent Document Code Number-Kind Code ² (if known)	Country	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	T ⁶
elle	1	WO/9745543 A		12-04-1997	Combadiere, Chrisophe et al.	
elle	2	WO/9747318 A		12-18-1997	Allaway, Graham P. et al.	

NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
elle	3	GHORPADE, A., XIA, M.Q., HYMAN, B.T., PERSODSKY, Y., NUKUNA, A., BOCK, P., CHE, M., LIMOGES, J., GENDELMAN, H.E. and MACKAY, C.R. (1998) Role of the beta-chemokine receptors CCR3 and CCR5 in human immunodeficiency virus type 1 infection of monocytes and microglia. J. Virol. 72: 3351-3361;	
	4	SCHOLS, D., PROOST, P., STRUYF, S., WUYTS, A., DE MEESTER, I., SCHARPE, S., VAN DAMME, J. and DE CLERCQ, E. (1999) CD26-processed RANTES(3-68), but not intact RANTES, has potent anti-HIV-1 activity. Antiviral Res. 39: 175-187;	
	5	SIMMONS, G., CLAPHAM, P.R., PICARD, L., OFFORD, R.E., ROSENKILDE, M.M., SCHWARTZ, T.W., BUSIER R., WELLS, T.N., PROUDFOOT, A.E. (1997) Potent inhibition of HIV-1 infectivity in macrophages and lymphocytes by a novel CCR5 antagonist. Science 276: 276-279;	
	6	LEHNER, T., DOYLE, C., WANG, Y., BABAAHMADY, K., WHITTALL, T., TAO, L., BERGMIEIER, L. and KELLY, C. (2001) Immunogenicity of the extracellular domains of C-C chemokine receptor 5 and the in vitro effects on simian immunodeficiency or HIV infectivity. J. Immunol. 166: 7446-7455; and	
	7	WU, L., PAXTON, W.A., KASSAM, N., RUFFING, N., ROTTMAN, J.B., SULLIVAN, N., CHOE, H., SODROSKI, J., NEWMAN, W., KOUP, R.A. and MACKAY, C.R. (1997) CCR5 levels and expression pattern correlate with infectability by macrophage-tropic HIV-1 in vitro, J. Exp. Med. 185: 1681-1691.	

EXAMINER SIGNATURE <i>Emily Le</i>	DATE CONSIDERED 11/27/00
------------------------------------	--------------------------

*EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609: Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹Applicant's unique citation designation number (optional). ² See Kinds of Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁶ Applicant is to place a check mark here if English Language Translation is attached.

Applicants: William C. Olson, et al.
Serial No.: 09/464,902
Filed: December 16, 1999
Exhibit A

Form PTO-1449 SEP 19 2005 U.S. Department of Commerce Patent and Trademark Office		Application Number 09/464,902 Filing Date December 16, 1999 First Named Inventor Olson et al. Art Unit 1648 Examiner Name Emily Lee Attorney Docket No. 57906-A/IPW/AG			
INFORMATION DISCLOSURE STATEMENT (Use separate sheets if necessary)					
U.S. PATENT DOCUMENTS					
Examiner Initials*	Cite No. ¹	Document Number Number-Kind Code ^{2,3} of Interest	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	
ole		6,025,154	10-10-2004		
		6,265,184	07-24-2001		
		6,268,477	07-31-2002		
		6,448,375	09-10-2002		
		6,743,594	06-01-2004		
		6,797,811	09-28-2004		
		6,261,763	07-17-2001		
		6,972,126	12-06-2005		
		2002-0150888	11-17-2002		
		2004-0161739	08-19-2004		
		2004-0230037	11-18-2004		
		2004-0110127	06-10-2004		
		2005-0154193	07-14-2005		
		2003-0100058	05-29-2003		
		2003-0166024	09-04-2003		
	2004-0151719	08-08-2004			
	2001-0000241	04-12-2001			
	2001-0046512	11-29-2001			
FOREIGN PATENT DOCUMENTS					
Examiner Initials*	Cite No. ¹	Foreign Patent Document Country Code Number* Kind Code ^{2,3} of Interest	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	T ⁴
ole		WO1995/16879	06-22-1995		
		WO1996/41020	12-19-1996		
		WO1997/37005	10-27-1997		
		WO1997/47319	12-18-1997		
		WO2002/064612	08/22/2002		
		WO2001/58915	08-16-2001		
EXAMINER SIGNATURE <i>Emily L</i>		DATE CONSIDERED 11/16/05			
<p>*EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹ Applicant's unique citation designation number (optional). ² See Kinds of Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbol as indicated on the document under WIPO Standard ST.16 if possible. ⁶ Applicant is to place a check mark here if English Language Translation is attached.</p>					

Applicants: William C. Olson
 and Paul J. Maddon
 U.S. Serial No. 09/464,902
 Filed: December 16, 1999
 Exhibit C

Application Number	09/464,902
Filing Date	December 16, 1999
First Named Inventor	Olson et al.
Art Unit	1648
Examiner Name	Emily Lee
Attorney Docket No.	57906-AJPW/AG

[illegible]

Examiner Initials*	Cite No. ¹	Foreign Patent Document Country Code*Number*Kind Code ² (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	T ³
llq		WO2001/58916	08-16-2001		
		WO1996/39437	12-12-1996		
		WO1997/22698	06-26-1997		
		WO1997/44055	11-27-1997		
		WO1997/032019	09-04-1997		
		EP 96870021.1	03-01-1996		
		EP 96870102.9	08-06-1996		
		EP 1145721	10-17-2001		
		EP 1146055	10-17-2001		
		EP 1146122	10-17-2001		

EXAMINER SIGNATURE <i>C. L.</i>	DATE CONSIDERED 11/16/06
------------------------------------	--------------------------

*EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. *Applicant's unique citation designation number (optional). * See Kinds of Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. * Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). * For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. * Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. * Applicant is to place a check mark here if English Language Translation is attached.

Form PTO-1449

U.S. Department of Commerce
Patent and Trademark OfficeINFORMATION DISCLOSURE STATEMENT
(Use several sheets if necessary)

Application Number	09/464,902
Filing Date	December 16, 1999
First Named Inventor	Olson et al.
Art Unit	1648
Examiner Name	Emily Lee
Attorney Docket No.	57906-AJPW/AG

U.S. PATENT DOCUMENTS

Examiner Initials ⁶	Cite No. ¹	Document Number Number-Kind Code ² (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document

FOREIGN PATENT DOCUMENTS

Examiner Initials ⁶	Cite No. ¹	Foreign Patent Document Country Code ³ Number ⁴ Kind Code ² (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	T ⁵
		EP 1148126	10-24-2001		
14		EP 1148127	10-24-2001		
		EP 1149582	10-31-2001		
		EP 1199360	04-24-2002		
		EP 1482042	12-01-2004		
		EP 815137	12-12-1996		
		EP 883687	11-27-2004		
		CA 2216990	12-27-1997		

EXAMINER
SIGNATURE

Emily L.

DATE CONSIDERED

11/16/06

⁶ EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹ Applicant's unique citation designation number (optional). ² See Kinds of Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁶ Applicant is to place a check mark here if English Language Translation is attached.

Form PTOL 449 U.S. Department of Commerce Patent and Trademark Office INFORMATION DISCLOSURE CITATION (Use several sheets if necessary)		Application Number 09/464,902 Filing Date December 16, 1999 First Named Inventor Olson et al. Art Unit 1648 Examiner Name Emily Lee Attorney Docket No. 57906-A/JPW/AG	
NON PATENT LITERATURE DOCUMENTS			
Examiner Initials	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ¹
eli		Dean, M. et al., (1996) "Genetic Restriction Of HIV-1 Infection And Progression To AIDS By A Deletion Allele Of The CKR5 Structural Gene", Science 273:1856-1862	
		He, J. et al., (1997) "CCR3 And CCR5 Are Co-Receptors For HIV-1 Infection Of Microglia", Nature 385:645-649	
		Konigs, C. et al., (2000) "Monoclonal Antibody Screening Of Phage-Displayed Random Peptide Library Reveals Mimotopes Of Chemokine Receptor CCR5: Implications For The Tertiary Structure Of The Receptor And For An N-Terminal Binding Site For HIV-1 Gp120", Eur. J. Immunol. 30(4):1162-1171	
		Lee, B. et al., (1999) "Epitope Mapping Of CCR5 Reveals Multiple Conformational States And Distinct But Overlapping Structures Involved In Chemokine Coreceptor Function", J. Biol. Chem. 274(14):9617-9626	
		Mackay, C.R., (1996) "Chemokine Receptors And T Cell Chemotaxis", J. Exp. Med 184:799-802	
		Raport, C.J. et al., (1996) "Molecular Cloning And Functional Characterization Of A Novel Human CC Chemokine Receptor (CCR5) For RANTES, MIP-1 β , And MIP-1 α ", J. Biol. Chem. 271(29):1761-17166	
		Samson, M. et al., (1996) "Molecular Cloning And Functional Expression Of A New Human CC-Chemokine Receptor Gene", Biochem. 35:3362-3367	
		Steinberger, P. et al., (2000) "Generation And Characterization Of A Recombinant Human CCR5-Specific Antibody", J. Biol. Chem. 275:36073-36078	
		Wu, L. et al., (1996) "CD4-Induced Interaction Of Primary HIV-1 Gp120 Glycoproteins With The Chemokine Receptor CCR-5", Nature 384:179-183	
EXAMINER SIGNATURE <i>Emily Lee</i>		DATE CONSIDERED 11/16/06	
<small>*EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹Applicant's unique citation designation number (optional). ²Applicant is to place a checkmark here if English language Translation is attached.</small>			